We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others. Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others.
Ask ADVFN Intelligence (AI)
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE’24 Phase 2 MaGic trial of DNTH103 in generalized...
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
NEW YORK and WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H’25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in...
NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic...
NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H’25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor...
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.66 | -10.64 | 25 | 25.1 | 19.845 | 312926 | 22.38048645 | CS |
| 4 | -5.79 | -20.5830074653 | 28.13 | 31.97 | 19.845 | 299641 | 25.79933432 | CS |
| 12 | -6.83 | -23.4144669181 | 29.17 | 31.97 | 19.845 | 247332 | 26.85938228 | CS |
| 26 | -2.33 | -9.44466963924 | 24.67 | 31.97 | 19.845 | 254326 | 26.55307469 | CS |
| 52 | 10.86 | 94.5993031359 | 11.48 | 33.77 | 6.58 | 186361 | 25.62280173 | CS |
| 156 | 11.94 | 114.807692308 | 10.4 | 33.77 | 6.58 | 159055 | 25.2891594 | CS |
| 260 | 11.94 | 114.807692308 | 10.4 | 33.77 | 6.58 | 159055 | 25.2891594 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
